

# NCTN Adolescent to Young Adult (AYA) Cancer Trials Portfolio (Open as of 4/15/2024)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and the study information.

## Newly Diagnosed Disease

## Recurrent Disease

**Rhabdomyosarcoma (RMS)**  
ARST2031 (High risk)

**Germ Cell Tumors**  
AGCT1531      AGCT1532

**Acute Lymphoblastic Leukemia (ALL)**  
AALL1821

**Osteosarcoma (Pulmonary Mets)**  
AOST2031

**Acute Lymphoblastic Leukemia (ALL)**  
A041501

**Classical Hodgkin Lymphoma**  
E4412

**Osteosarcoma (Metastatic)**  
AOST2032

**Nongerminomatous germ cell tumor of the CNS**  
ACNS2021

**Osteosarcoma (Pulmonary Mets)**  
AOST2031

**Classical Hodgkin Lymphoma**  
AHOD2131

**Mediastinal (thymic) large B-cell lymphoma**  
ANHL1931

### Legend by Disease Types

Green = Rhabdomyosarcoma (RMS)

Yellow = Germ Cell Tumors

Orange = Hodgkin Lymphoma

Blue = ALL

Lime Green = Osteosarcoma

Light Purple = CNS NGGCT

Gray = PMBCL

## NCTN Adolescent to Young Adult (AYA) Cancer Trials (Open as of 4/15/2024)

Protocol Number	Phase	Protocol Title
<b>A041501</b>	III	A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
<b>AALL1821</b>	II	A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged $\geq 1$ to $< 31$ Years Old with First Relapse
<b>ACNS2021</b>	II	A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
<b>AGCT1531</b>	III	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
<b>AGCT1532</b>	III	A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell Tumors
<b>ANHL1931</b>	III	A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
<b>AHOD2131</b>	III	A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
<b>AOST2031</b>	III	A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
<b>AOST2032</b>	II/III	A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
<b>ARST2031</b>	III	A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
<b>E4412</b>	I/II	A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

This portfolio shows NCTN trials. For information about NCORP trials, please see: <https://ncorp.cancer.gov/find-a-study/>